John Wagner, MD
Medical Oncology · Charlottesville, VANPI 1346262607
Payments from drug & device makers
What this record shows
4 manufacturers reported payments, led by National Marrow Donor Program at 53.2% of the total. Reporting peaked in 2024 at $790 and has fallen 75.6% since, to $193 in 2025.
Across 7 payments — averaging $207.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- National Marrow Donor Program$772
- GSK$430
- AstraZeneca$175
- Astellas Pharma US Inc$74
Across 64 payments — averaging $2016.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$129K
What the payments were for
- Consulting fees$60542%
- Food & beverage$84658%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| National Marrow Donor Program | 1 | $772 |
| GSK | 1 | $430 |
| AstraZeneca | 1 | $175 |
| Astellas Pharma US Inc | 4 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,451 in reported general payments places this provider in the 55th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrevymisLetermovir | 11 | $61,460 |
| Acyclovir | 78 | $1,863 |
| Ondansetron OdtOndansetron | 15 | $206 |
| Pantoprazole Sodium | 13 | $181 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $44 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Charlottesville
- Robert DreicerCharlottesville$296K
- Ryan GentzlerCharlottesville$62K
- Matthew ReilleyCharlottesville$37K
- Enrica MarchiCharlottesville$30K
- Richard HallCharlottesville$29K
- Paul ViscuseCharlottesville$12K
- Ludimila CavalcanteCharlottesville$7K
- William SkeltonCharlottesville$6K
- Paul KunkCharlottesville$4K
- Patrick DillonCharlottesville$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.